MedTrace Logo

The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive Impairment

NCT05022186 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-08-26

No results posted yet for this study

Summary

A Randomized Clinical Trial that will compare the effects of Cannabidiol and Homotaurine in cognition and mental health in patients with Mild Cognitive Impairment and APOE ε4 carriers. Ninety patients will be recruited and they will be randomly distributed in three groups. The first group will receive treatment with Cannabidiol 5%, the second group will receive treatment with Vivimind and the third group will not receive any treatment. The three groups will be compared by using an extensive neuropsychological examination and biomarkers' results from cerebrospinal fluid and blood

Conditions

Interventions

DRUG

Cannabidiol Oil

Patients will use it with specific instructions and they will be monitored at least one time in a month

DRUG

Homotaurine

Patients will use it with specific instructions and they will be monitored at least one time in a month

Sponsors & Collaborators

  • Greek Alzheimer's Association and Related Disorders

    collaborator OTHER

  • Aristotle University Of Thessaloniki

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-20
Completion
2022-12-20

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05022186 on ClinicalTrials.gov